Table 15Results of meta-analyses for mean change in HbA1c and weight for sitagliptin 100 mg compared with placebo

OutcomeNPooled analysisHeterogeneity
MeasureUnitsEstimate95% CIP valueI2
HbA1c7aWMD%−0.79(−0.933; −0.664)<0.00166%
Weight5bWMDKg0.66(0.43; 0.892)<0.0010.3%
a

Included studies for this outcome: Aschner (2006), Raz (2006), Nonaka (2008), Goldstein (2007), Scott (2007), Mohan (2009), Hanefeld (2007)

b

Included studies for this outcome: Aschner (2006), Raz (2006), Mohan (2009), Nonaka (2008), Goldstein (2007)

From: Results

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.